Blood filtering shows promise for severe COVID-19 patients
NCT ID NCT04751643
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether filtering the blood (therapeutic plasma exchange) could help severe COVID-19 patients by removing harmful immune molecules that cause lung damage. Twenty-one adults in intensive care with COVID-19 and lung failure were randomly assigned to receive either blood filtering plus standard care or standard care alone. The main goal was to see if the treatment reduced the need for a breathing tube.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
therapeutic plasma exchange (blood filtering)
What this could lead to
If it works, this could provide a way to quickly calm the immune overreaction in severe COVID-19, potentially reducing the need for breathing machines.
What could go wrong
This was a very small, early trial with only 21 participants, so results may not apply broadly. Plasma exchange also carries risks like allergic reactions or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
-
Centre Hospitalier William Morey
Chalon-sur-Saône, 71100, France
-
Clinique de la Sauvegarde
Lyon, 69337, France
-
Groupement Hospitalier Porte de Valence - Montélimar
Montélimar, 26216, France
-
Hôpital Croix Rousse
Lyon, 69004, France
-
Hôpital Edouard Herriot
Lyon, 69003, France
-
Hôpital Pitié Salpétrière - Assistante Publique des Hôpitaux de Paris
Paris, 75013, France
-
Medipole Villeurbanne
Villeurbanne, 69100, France